These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 35188645)

  • 41. Chemical hazard prediction and hypothesis testing using quantitative adverse outcome pathways.
    Perkins EJ; Gayen K; Shoemaker JE; Antczak P; Burgoon L; Falciani F; Gutsell S; Hodges G; Kienzler A; Knapen D; McBride M; Willett C; Doyle FJ; Garcia-Reyero N
    ALTEX; 2019; 36(1):91-102. PubMed ID: 30332685
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A toxicity pathway-oriented approach to develop adverse outcome pathway: AHR activation as a case study.
    Jin Y; Feng M; Ma W; Wei Y; Qi G; Luo J; Xu L; Li X; Li C; Wang Y; Li D; Chen J; Zhao Y; Hou Y; Zhao Q; Jiang L; Xie M; Zheng Y; Yu D
    Environ Pollut; 2021 Jan; 268(Pt B):115733. PubMed ID: 33011576
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Integrated Approaches to Testing and Assessment: OECD Activities on the Development and Use of Adverse Outcome Pathways and Case Studies.
    Sakuratani Y; Horie M; Leinala E
    Basic Clin Pharmacol Toxicol; 2018 Sep; 123 Suppl 5():20-28. PubMed ID: 29316278
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Application of the adverse outcome pathway framework to genotoxic modes of action.
    Sasaki JC; Allemang A; Bryce SM; Custer L; Dearfield KL; Dietz Y; Elhajouji A; Escobar PA; Fornace AJ; Froetschl R; Galloway S; Hemmann U; Hendriks G; Li HH; Luijten M; Ouedraogo G; Peel L; Pfuhler S; Roberts DJ; Thybaud V; van Benthem J; Yauk CL; Schuler M
    Environ Mol Mutagen; 2020 Jan; 61(1):114-134. PubMed ID: 31603995
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The future trajectory of adverse outcome pathways: a commentary.
    Sewell F; Gellatly N; Beaumont M; Burden N; Currie R; de Haan L; Hutchinson TH; Jacobs M; Mahony C; Malcomber I; Mehta J; Whale G; Kimber I
    Arch Toxicol; 2018 Apr; 92(4):1657-1661. PubMed ID: 29549413
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A quantitative AOP of mitochondrial toxicity based on data from three cell lines.
    Tebby C; Gao W; Delp J; Carta G; van der Stel W; Leist M; Jennings P; van de Water B; Bois FY
    Toxicol In Vitro; 2022 Jun; 81():105345. PubMed ID: 35278637
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Extracting and Benchmarking Emerging Adverse Outcome Pathway Knowledge.
    Pollesch NL; Villeneuve DL; O'Brien JM
    Toxicol Sci; 2019 Apr; 168(2):349-364. PubMed ID: 30715536
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Is there a role for the adverse outcome pathway framework to support radiation protection?
    Chauhan V; Said Z; Daka J; Sadi B; Bijlani D; Marchetti F; Beaton D; Gaw A; Li C; Burtt J; Leblanc J; Desrosiers M; Stuart M; Brossard M; Vuong NQ; Wilkins R; Qutob S; McNamee J; Wang Y; Yauk C
    Int J Radiat Biol; 2019 Feb; 95(2):225-232. PubMed ID: 30373433
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Molecular Pathway and AOP Development Using Gene Network Analysis].
    Tanabe S; Hirose A; Whelan M; Yamada T
    Yakugaku Zasshi; 2020; 140(4):485-489. PubMed ID: 32238629
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A strategy towards the generation of testable adverse outcome pathways for nanomaterials.
    Murugadoss S; Vinković Vrček I; Pem B; Jagiello K; Judzinska B; Sosnowska A; Martens M; Willighagen EL; Puzyn T; Dusinska M; Cimpan MR; Fessard V; Hoet PH
    ALTEX; 2021; 38(4):580-594. PubMed ID: 34008034
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The identification of nuclear receptors associated with hepatic steatosis to develop and extend adverse outcome pathways.
    Mellor CL; Steinmetz FP; Cronin MT
    Crit Rev Toxicol; 2016 Feb; 46(2):138-52. PubMed ID: 26451809
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A case example of a radiation-relevant adverse outcome pathway to lung cancer.
    Chauhan V; Sherman S; Said Z; Yauk CL; Stainforth R
    Int J Radiat Biol; 2021; 97(1):68-84. PubMed ID: 31846388
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Non-Animal Strategies for Toxicity Assessment of Nanoscale Materials: Role of Adverse Outcome Pathways in the Selection of Endpoints.
    Halappanavar S; Nymark P; Krug HF; Clift MJD; Rothen-Rutishauser B; Vogel U
    Small; 2021 Apr; 17(15):e2007628. PubMed ID: 33559363
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Application of AOPs to assist regulatory assessment of chemical risks - Case studies, needs and recommendations.
    Bajard L; Adamovsky O; Audouze K; Baken K; Barouki R; Beltman JB; Beronius A; Bonefeld-Jørgensen EC; Cano-Sancho G; de Baat ML; Di Tillio F; Fernández MF; FitzGerald RE; Gundacker C; Hernández AF; Hilscherova K; Karakitsios S; Kuchovska E; Long M; Luijten M; Majid S; Marx-Stoelting P; Mustieles V; Negi CK; Sarigiannis D; Scholz S; Sovadinova I; Stierum R; Tanabe S; Tollefsen KE; van den Brand AD; Vogs C; Wielsøe M; Wittwehr C; Blaha L
    Environ Res; 2023 Jan; 217():114650. PubMed ID: 36309218
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An adverse outcome pathway-based approach to assess steatotic mixture effects of hepatotoxic pesticides in vitro.
    Lichtenstein D; Luckert C; Alarcan J; de Sousa G; Gioutlakis M; Katsanou ES; Konstantinidou P; Machera K; Milani ES; Peijnenburg A; Rahmani R; Rijkers D; Spyropoulou A; Stamou M; Stoopen G; Sturla SJ; Wollscheid B; Zucchini-Pascal N; Braeuning A; Lampen A
    Food Chem Toxicol; 2020 May; 139():111283. PubMed ID: 32201337
    [TBL] [Abstract][Full Text] [Related]  

  • 56. AOP-helpFinder webserver: a tool for comprehensive analysis of the literature to support adverse outcome pathways development.
    Jornod F; Jaylet T; Blaha L; Sarigiannis D; Tamisier L; Audouze K
    Bioinformatics; 2022 Jan; 38(4):1173-1175. PubMed ID: 34718414
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Why adverse outcome pathways need to be FAIR.
    Wittwehr C; Clerbaux LA; Edwards S; Angrish M; Mortensen H; Carusi A; Gromelski M; Lekka E; Virvilis V; Martens M; Bonino da Silva Santos LO; Nymark P
    ALTEX; 2024 Jan; 41(1):50-56. PubMed ID: 37528748
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of an adverse outcome pathway network for breast cancer: a comprehensive representation of the pathogenesis, complexity and diversity of the disease.
    Del'haye GG; Nulmans I; Bouteille SP; Sermon K; Wellekens B; Rombaut M; Vanhaecke T; Vander Heyden Y; De Kock J
    Arch Toxicol; 2022 Nov; 96(11):2881-2897. PubMed ID: 35927586
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Pragmatic Approach to Adverse Outcome Pathway Development and Evaluation.
    Svingen T; Villeneuve DL; Knapen D; Panagiotou EM; Draskau MK; Damdimopoulou P; O'Brien JM
    Toxicol Sci; 2021 Nov; 184(2):183-190. PubMed ID: 34534351
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Toxicogenomics Data for Chemical Safety Assessment and Development of New Approach Methodologies: An Adverse Outcome Pathway-Based Approach.
    Saarimäki LA; Morikka J; Pavel A; Korpilähde S; Del Giudice G; Federico A; Fratello M; Serra A; Greco D
    Adv Sci (Weinh); 2023 Jan; 10(2):e2203984. PubMed ID: 36479815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.